Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis.

Thamsborg G, Jensen JE, Kollerup G, Hauge EM, Melsen F, Sorensen OH

Bone1 Feb 1996Cited by 37 (Europe PMC)

PMID8833216DOI10.1016/8756-3282(95)00447-5PepBankPUB-08833216

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with prior Colles' fracture, the lumbar spine BMD difference between calcitonin and placebo was not significant.
In plain wordsIn postmenopausal women with prior wrist fracture, spine bone density did not significantly differ between calcitonin and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeLumbar spine BMD difference
Study
n = 62
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 24 monthsAs given in this study (human).
Measurements
Between-group BMD difference
0.8%
reported result
95% CI
−1.2 to 3%
reported result
Source sentences
Summary
but the difference between the groups was not significant (0.8%; 95% confidence interval -1.2-3.0%).
2 context sentences(design, population, supporting numbers)
Summary · context
62 women (mean age 65 years) who had experienced Colles' fracture after menopause were randomized to receive either nasal salmon calcitonin (SCT) 200 IU or nasal placebo daily for 24 months.
Summary · context
All received a daily supplement of 0.5 g calcium.
Report a problemFND-0883321602
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with prior Colles' fracture, osteocalcin was significantly lower with calcitonin than placebo at months 12 and 24.
In plain wordsIn postmenopausal women with prior wrist fracture, blood osteocalcin was lower with calcitonin than placebo.
Peptide
Calcitonin-salmon
Outcome
DecreaseOsteocalcin at months 12 and 24
Study
n = 62
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 24 monthsAs given in this study (human).
Measurements
P value
< 0.03
osteocalcin, calcitonin versus placebo at months 12 and 24
Source sentences
Summary
At months 12 and 24, serum levels of osteocalcin were significantly lower in the SCT group than in the placebo group (p < 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
62 women (mean age 65 years) who had experienced Colles' fracture after menopause were randomized to receive either nasal salmon calcitonin (SCT) 200 IU or nasal placebo daily for 24 months.
Summary · context
All received a daily supplement of 0.5 g calcium.
Report a problemFND-0883321604
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with prior Colles' fracture, urinary deoxypyridinoline/creatinine did not significantly differ between calcitonin and placebo.
In plain wordsIn postmenopausal women with prior wrist fracture, the urinary bone breakdown marker did not significantly differ between calcitonin and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeUrinary deoxypyridinoline/creatinine difference
Study
n = 62
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 24 monthsAs given in this study (human).
Source sentences
Summary
The differences between the groups were, however, not significant.
3 context sentences(design, population, supporting numbers)
Summary · context
Urinary levels of deoxypyridinoline/creatinine decreased significantly below baseline in the SCT group, whereas only a transient decrease was observed in the placebo group.
Summary · context
62 women (mean age 65 years) who had experienced Colles' fracture after menopause were randomized to receive either nasal salmon calcitonin (SCT) 200 IU or nasal placebo daily for 24 months.
Summary · context
All received a daily supplement of 0.5 g calcium.
Report a problemFND-0883321606
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with prior Colles' fracture, erosion depth was significantly lower with calcitonin than placebo after 12 months.
In plain wordsIn postmenopausal women with prior wrist fracture, bone erosion depth was lower with calcitonin than placebo.
Peptide
Calcitonin-salmon
Outcome
DecreaseErosion depth
Study
n: not reported in source
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 12 monthsAs given in this study (human).
Measurements
Median erosion depth
46.9 mu m
calcitonin
Interquartile range
10.4 mu m
calcitonin
Median erosion depth
50.5 mu m
placebo
Interquartile range
10.7 mu m
placebo
P value
0.03
erosion depth, calcitonin versus placebo at 12 months
Source sentences
Summary
The erosion depth was significantly lower in the SCT group than in the placebo group after 12 months (median [interquartile range]; 46.9 mu m [10.4] vs. 50.5 mu m [10.7]; p = 0.03), whereas bone volume and activation frequency did not differ between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
62 women (mean age 65 years) who had experienced Colles' fracture after menopause were randomized to receive either nasal salmon calcitonin (SCT) 200 IU or nasal placebo daily for 24 months.
Summary · context
All received a daily supplement of 0.5 g calcium.
Report a problemFND-0883321607
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with prior Colles' fracture, bone volume did not differ between calcitonin and placebo.
In plain wordsIn postmenopausal women with prior wrist fracture, bone volume did not differ between calcitonin and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeBone volume
Study
n: not reported in source
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 12 monthsAs given in this study (human).
Source sentences
Summary
The erosion depth was significantly lower in the SCT group than in the placebo group after 12 months (median [interquartile range]; 46.9 mu m [10.4] vs. 50.5 mu m [10.7]; p = 0.03), whereas bone volume and activation frequency did not differ between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
62 women (mean age 65 years) who had experienced Colles' fracture after menopause were randomized to receive either nasal salmon calcitonin (SCT) 200 IU or nasal placebo daily for 24 months.
Summary · context
All received a daily supplement of 0.5 g calcium.
Report a problemFND-0883321608
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal women with prior Colles' fracture, activation frequency did not differ between calcitonin and placebo.
In plain wordsIn postmenopausal women with prior wrist fracture, bone remodeling activation frequency did not differ between calcitonin and placebo.
Peptide
Calcitonin-salmon
Outcome
No significant changeActivation frequency
Study
n: not reported in source
Comparator
placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 12 monthsAs given in this study (human).
Source sentences
Summary
The erosion depth was significantly lower in the SCT group than in the placebo group after 12 months (median [interquartile range]; 46.9 mu m [10.4] vs. 50.5 mu m [10.7]; p = 0.03), whereas bone volume and activation frequency did not differ between the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
62 women (mean age 65 years) who had experienced Colles' fracture after menopause were randomized to receive either nasal salmon calcitonin (SCT) 200 IU or nasal placebo daily for 24 months.
Summary · context
All received a daily supplement of 0.5 g calcium.
Report a problemFND-0883321609
07HumanNon-randomized trialEfficacy outcome
In postmenopausal women with prior Colles' fracture, lumbar spine BMD rose significantly above baseline after 24 months in both the calcitonin group (2.5%) and the placebo group (1.7%).
In plain wordsIn postmenopausal women with prior wrist fracture, spine bone density rose from baseline in both the calcitonin and placebo groups.
Peptide
Calcitonin-salmon
Outcome
IncreaseLumbar spine BMD change
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 24 monthsAs given in this study (human).
Measurements
BMD increase
2.5%
calcitonin
95% CI
0.9 to 4.2%
calcitonin
BMD increase
1.7%
placebo
95% CI
0.3 to 3.1%
placebo
Source sentences
Summary
There was a significant increase above baseline in the bone mineral density of the lumbar spine in the SCT group (2.5%; 95% confidence interval 0.9--4.2%) and in the placebo group (1.7%; 95% confidence interval 0.3--3.1%) after 24 months
2 context sentences(design, population, supporting numbers)
Summary · context
62 women (mean age 65 years) who had experienced Colles' fracture after menopause were randomized to receive either nasal salmon calcitonin (SCT) 200 IU or nasal placebo daily for 24 months.
Summary · context
All received a daily supplement of 0.5 g calcium.
Report a problemFND-0883321601
08HumanNon-randomized trialEfficacy outcome
In postmenopausal women with prior Colles' fracture, serum osteocalcin decreased significantly below baseline with calcitonin.
In plain wordsIn postmenopausal women with prior wrist fracture, blood osteocalcin decreased during calcitonin treatment.
Peptide
Calcitonin-salmon
Outcome
DecreaseOsteocalcin change
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 24 monthsAs given in this study (human).
Source sentences
Summary
Serum levels of osteocalcin decreased significantly below baseline in the SCT group, whereas they were unchanged in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
62 women (mean age 65 years) who had experienced Colles' fracture after menopause were randomized to receive either nasal salmon calcitonin (SCT) 200 IU or nasal placebo daily for 24 months.
Summary · context
All received a daily supplement of 0.5 g calcium.
Report a problemFND-0883321603
09HumanNon-randomized trialEfficacy outcome
In postmenopausal women with prior Colles' fracture, urinary deoxypyridinoline/creatinine decreased significantly below baseline with calcitonin, whereas the placebo group showed only a transient decrease.
In plain wordsIn postmenopausal women with prior wrist fracture, a urinary bone breakdown marker decreased during calcitonin treatment, while placebo showed only a transient decrease.
Peptide
Calcitonin-salmon
Outcome
DecreaseUrinary deoxypyridinoline/creatinine change
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
200 IU daily · intranasal · 24 monthsAs given in this study (human).
Source sentences
Summary
Urinary levels of deoxypyridinoline/creatinine decreased significantly below baseline in the SCT group, whereas only a transient decrease was observed in the placebo group.
2 context sentences(design, population, supporting numbers)
Summary · context
62 women (mean age 65 years) who had experienced Colles' fracture after menopause were randomized to receive either nasal salmon calcitonin (SCT) 200 IU or nasal placebo daily for 24 months.
Summary · context
All received a daily supplement of 0.5 g calcium.
Report a problemFND-0883321605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.